Status:

UNKNOWN

Carnosine for Peripheral Vascular Disease

Lead Sponsor:

Monash University

Collaborating Sponsors:

Monash Health

Conditions:

Peripheral Arterial Disease

Eligibility:

All Genders

40-80 years

Phase:

PHASE2

Brief Summary

The investigators hypothesise that a home-based standardised exercise intervention with 2g of carnosine daily for 6 months will improve walking endurance in 104 patients with PVD aged 40-80 years comp...

Detailed Description

Peripheral vascular disease (PVD) has high prevalence of 10-15% in Australia and is caused by atherosclerotic occlusion of the arteries supplying the lower extremities which reduces blood flow and lea...

Eligibility Criteria

Inclusion

  • Age \>=40or \<80 years
  • Clinical diagnosis Peripheral Vascular disease
  • Rutherford Grade 1-3
  • No significant kidney, cardiovascular, haematological, respiratory, gastrointestinal, or central nervous system disease, as well as no psychiatric disorders, no active cancer within the last five years; no presence of acute inflammation (by history, physical or laboratory examination)
  • Intermittent claudication on treadmill between 30m and 200m
  • Ankle Brachial index 0.6-1 at rest with minimum post exercise drop in ABI of 0.1

Exclusion

  • Age \< 40 or \> 80 years
  • Pregnant or lactating
  • Limb threatening ischaemia- Rutherford grades 4-6, manifested by ischaemic rest pain, ulceration, or gangrene; acute limb-threatening ischaemia
  • lower limb surgical or endovascular interventions in the preceding 6 months
  • planned lower limb endovascular or surgical intervention within the next 6 months on either limb
  • taking medication for PVD (Cilostazol and Pentoxifylline)
  • inability to complete the treadmill walking test for reasons other than claudication
  • myocardial infarction within last 3 months
  • deep vein thrombosis within 3 months
  • estimated life expectancy \< 1 year
  • alcohol and illicit drug abuse.

Key Trial Info

Start Date :

March 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2022

Estimated Enrollment :

104 Patients enrolled

Trial Details

Trial ID

NCT03844113

Start Date

March 1 2019

End Date

December 31 2022

Last Update

December 29 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Monash Centre for Health Research and Implementation

Melbourne, Victoria, Australia, 3168